Protein mass spectra data analysis for clinical biomarker discovery: A global review

Briefings in Bioinformatics

Volumn 12, Issue 2, 2011, Pages 176-186

  Roy, Pascal ^a,b,c   Truntzer, Caroline ^d   Maucort Boulch, Delphine ^f   Jouve, Thomas ^f   Molinari, Nicolas ^e  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ DE LYON   (France)

^c LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^d DIJON UNIVERSITY HOSPITAL   (France)

^e NÎMES UNIVERSITY HOSPITAL   (France)

^f NONE

Author keywords

Biomarker identification; Clinical proteomics; Pre processing; Statistics; Validation

Indexed keywords

BIOLOGICAL MARKER; PROTEIN;

CHEMISTRY; MASS SPECTROMETRY; METHODOLOGY; PROTEOMICS; REVIEW;

BIOLOGICAL MARKERS; MASS SPECTROMETRY; PROTEINS; PROTEOMICS;

EID: 79953139278     PISSN: 14675463     EISSN: 14774054     Source Type: Journal    
DOI: 10.1093/bib/bbq019     Document Type: Review

References (86)

1. Diamandis EP. How are we going to discover new cancer biomarkers? A proteomic approach for bladder cancer. Clin Chem 2004;50:793-5.
2. Semmes OJ, Feng Z, Adam BL, et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I assessment of platform reproducibility. Clin Chem 2005;51:102-12.
3. West-Nørager M, Kelstrup CD, Schou C, et al. Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics. J Chromatogr B AnalytTechnol Biomed Life Sci 2007;847:30-7.
4. Lin Z, Jenson SD, Lim MS, et al. Application of SELDITOF mass spectrometry for the identication of differentially expressed proteins in transformed follicular lymphoma. Mod Pathol 2004;17:670-8.
5. Baggerly KA, Morris JS, Coombes KR. Reproducibility of seldi-tof protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004;20:777-85.
6. Coombes KR, Baggerly KR, Morris JS. Pre-ProcessingMass Spectrometry Data, Fundamentals of Data Mining in Genomics and Proteomics. Boston: Kluwer, 2007.
7. Hu J, Coombes KR, Morris JS, et al. The importance of experimental design in proteomic mass spectrometry experiments: Some cautionary tales. Brief Funct Genomic Proteomic 2005;3:322-31.
8. Arneberg R, Rajalahti T, Flikka K, et al. Pretreatment of mass spectral profiles: application to proteomic data. Anal Chem 2007;79:7014-26.
9. Morris JS, Coombes KR, Koomen J, et al. Feature extraction and quantification for mass spectrometry in biomedical applications using the mean spectrum. Bioinformatics 2005; 21:1764-75.
10. Cruz-Marcelo A, Guerra R, Vannucci M, et al. Comparison of algorithms for pre-processing of SELDI-TOF mass spectrometry data. Bioinformatics 2008;24:2129-36.
11. Yang C, He Z, Yu W. Comparison of public peak detection algorithms for MALDI mass spectrometry data analysis. BMC Bioinformatics 2009;10:4.
12. Antoniadis A, Bigot J, Lambert-Lacroix S, et al. Nonparametric pre-processing methods and inference tools for analyzing time-of-flight mass spectrometry data. Curr Anal Chem 2007;3:127-47.
13. Coombes KR, Tsavachidis S, Morris JS, et al. Improved peak detection and quantification of mass spectrometry data acquired from surface-enhanced laser desorption and ionization by denoising spectra with the undecimated discrete wavelet transform. Proteomics 2005;5:4107-17.
14. Du P, Kibbe WA, Lin SM. Improved peak detection in mass spectrum by incorporating continuous wavelet transformbased pattern matching. Bioinformatics 2006;22: 2059-65.
15. Kwon D, Vannucci M, Song JJ, et al. A novel wavelet-based thresholding method for the pre-processing of mass spectrometry data that accounts for heterogeneous noise. Proteomics 2008;8:3019-29.
16. Mostacci E, Truntzer C, Cardot H, et al. Multivariate denoising methods combining Wavelets and PCA for mass spectrometry data. Proteomics. In Press.
17. Fung ET, Enderwick C. ProteinChip clinical proteomics: computational challenges and solutions. Biotechniques 2002; 34(Suppl 8):40-1.
18. Tan CS, Ploner A, Quandt A, et al. Finding regions of significance in SELDI measurements for identifying protein biomarkers. Bioinformatics 2006;22:1515-23.
19. Li X. PROcess: Ciphergen SELDI-TOF Processing. 2005.R package version 1.16.0.
20. Malyarenko DI, Cooke WE, Adam BL, et al. Enhancement of sensitivity and resolution of surface-enhanced laser desorption/ionization time-of-flight mass spectrometric records for serum peptides using time-series analysis techniques. Clin Chem 2005;51:65-74.
21. Dijkstra M, Roelofsen H, Vonk RJ, et al. Peak quantification in surface-enhanced laser desorption/ionization by using mixture models. Proteomics 2006;6: 5106-16.
22. Jeffries N. Algorithms for alignment of mass spectrometry proteomic data. Bioinformatics 2005;21:3066-73.
23. Wong JWH, Cagney G, Cartwright HM. SpecAlign_processing and alignment of mass spectra datasets. Bioinformatics 2005;21:2088-90.
24. Pratapa PN, Patz EF, Hartemink AJ. Finding diagnostic biomarkers in proteomic spectra. Pac Symp Biocomput. New Jersey: World Scientific, 2006;279-90.
25. Kong X, Reilly CA. Bayesian approach to the alignment of mass spectra. Bioinformatics 2009;25:3213-20.
26. Feng Y, Ma W, Wang Z, et al. Alignment of protein mass spectrometry data by integrated Markov chain shifting method. Statistics and Its Interface 2009;2:329-40.
27. Cairns DA, Thompson D, Perkins DN, et al. Proteomic profiling using mass spectrometry - does normalising by total ion current potentially mask some biological differences? Proteomics 2008;8:21-7.
28. Meuleman W, Engwegen J, Gast M, et al. Comparison of normalisation methods for surface-enhanced laser desorption and ionisation (seldi) time-of-flight (tof) mass spectrometry data. BMC Bioinformatics 2008;9:88.
29. Yasui Y, Pepe M, Thompson ML, et al. A data analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. Biostatistics 2003;4:449-63.
30. Coombes KR, Fritsche J, Clarke C, et al. Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. Clin Chem 2003;49:1615-23.
31. Randolph TW, Mitchell BL, McLerran DF, et al. Quantifying peptide signal in MALDI-TOF mass spectrometry data. Mol Cell Proteomics 2005;4:1990-9.
32. Lange E, Gropl C, Reinert K, et al. High accuracy peak picking of proteomics data using wavelet techniques. Pacific Symposium on Biocomputing Maui, Hawaii, USA. New Jersy: Word Scientific, 2006;243-54.
33. Noy K, Fasulo D. Improved model-based, platformindependent feature extraction for mass spectrometry. Bioinformatics 2007;23:2528-35.
34. Du P, Angeletti RH. Automatic deconvolution of isotoperesolved mass spectra Using variable selection and quantized peptide mass distribution. Anal Chem 2006;78:3385-92.
35. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. JNCI 2001;93: 1054-61.
36. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). JNCI 2005;97:1180-4.
37. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. JRSS B 1995;57:289-300.
38. Dudoit S, Shaffer J, Boldrick J. Multiple hypothesis testing in microarray experiments. Stat Sci 2003;18:71-103.
39. Storey JD, Tibshirani R. Statistical significance for genomewide studies. ProcNatl Acad SciUSA 2004;100:9440-5.
40. Lee M-LT, Whitmore GA. Power and sample size for DNA microarray studies. StatMed 2002;21:3543-70.
41. Pawitan Y, Murthy KR, Michiels S, et al. Bias in the estimation of false discovery rate in microarray studies. Bioinformatics 2005;21(20):3865-72.
42. Truntzer C, Maucort-Boulch D, Roy P. Consequences of regression to the mean in the high dimensional setting 2010. submitted manuscript.
43. Truntzer C, Maucort-Boulch D, Roy P. Comparative optimism in models involving both classical clinical and gene expression information. BMC Bioinformatics 2008;9:434.
44. Efron B, Hastie T, Johnstone I, et al. Least angle regression. Ann Stat 2004;32:407-51.
45. Tibshirani R. Regression shrinkage and selection via the Lasso. JRStat Soc B 1996;58:267-88.
46. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning. 3rd edn. New York: Springer Science, 2009.
47. Friedman J, Popescu B. Gradient directed regularization for linear regression and classification. Technical Report, Stanford University, Department of Statistics, 2004.
48. Gui J, Li H. Penalized Cox regression analysis in the highdimensional and low-sample size settings, with applications to microarray gene expression data. Bioinformatics 2005;21: 3001-8.
49. Truntzer C, Mercier C, Estève J, et al. Importance of data structure in comparing two dimension reduction methods for classification of microarray gene expression data. BMC Bioinformatics 2007;8:90.
50. Boulesteix AL. PLS dimension reduction for classification with microarray data. Stat Appl Genet Mol Biol 2004;3: Article33.
51. Wu B, Abbott T, Fishman D, et al. Comparison of statistical methods for classification of ovarian cancer using mass spectrometry data. Bioinformatics 2003;19:1636-43.
52. Lê Cao KA, Rossouw D, Robert-Granié C, et al. A sparse PLS for variable selection when integrating omics data. Stat Appl Genet Mol Biol 2008;7:Article 35.
53. Reynes C, Sabatier R, Molinari N, et al. A new genetic algorithm in proteomics: feature selection for SELDI-TOF data. Comput Stat Data Anal 2008;52:4380-94.
54. Koomen JM, Shih LN, Coombes KR, et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res 2005;11: 1110-8.
55. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
56. Li L, Umbach DM, Terry P, et al. Application of the GA/KNN method to SELDI proteomics data. Bioinformatics 2004;20:1638-40.
57. Tong W, Xie Q, Hong H, et al. Using decision forest to classify prostate cancer samples on the basis of SELDITOF MS data: assessing chance correlation and prediction confidence. EnvironHealth Perspect 2004;112:1622-7.
58. Efron B, Tibshirani R. An introduction to the bootstrap. Monographs on Statistics & Applied Probability. New York: Chapman & Hall/CRC, 1993.
59. Shao J, Tu D. The Jackknife and Bootstrap. New York: Springer, 1995.
60. Altman DG, Royston P. What do we mean by validating a prognostic model? StatMed 2000;29:453-73.
61. Harrell F. Regression Modelling Strategy with Applications in Linear Models, Logistic Regression and Survival Model. New York: Springer, 2002.
62. Hilario M, Kalousis A, Pellegrini C, et al. Processing and classification of protein mass spectra. Mass Spectrom Rev 2006;25:409-49.
63. Pepe MS, Janes H, Longton G, et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. AmJ Epidemiol 2004;159:882-90.
64. Shiu SY, Gatsonis C. The predictive receiver operating characteristic curve for the joint assessment of the positive and negative predictive values. PhilTrans RSoc A 2008;366: 2313-33.
65. Jouve T, Maucort-Boulch D, Ducoroy P, et al. Statistical power in mass-spectrometry proteomic studies. submitted manuscript.
66. Albrethsen J. Reproducibility in protein profiling by malditof mass spectrometry. Clin Chem 2007;53:852-8.
67. Villanueva J, Lawlor K, Toledo-Crow R, et al. Automated serum peptide profiling. Nat Protoc 2006;1:880-91.
68. Callesen AK, Vach W, Jørgensen PE, et al. Reproducibility of mass spectrometry based protein profiles for diagnosis of breast cancer across clinical studies: a systematic review. J ProteomeRes 2008;7:1395-402.
69. Hu J, Coombes KR, Morris JS, et al. The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales. Brief Funct Genomic Proteomic 2005;3:322-31.
70. Oberg A, Vitek O. Statistical design of quantitative mass spectrometry-based proteomic profiling experiments. J ProteomeRes 2009;8:2144-56.
71. Cairns DA, Barrett JH, Billingham LJ, et al. Sample size determination in clinical proteomic profiling experiments using mass spectrometry for class comparison. Proteomics 2009;9:74-86.
72. Dettling M, Bühlmann P. Finding predictive gene groups from microarray data. JMultivarAnal 2004;90(1):106-31.
73. Gevaert O, Smet FD, Timmerman D, et al. Predicting the prognosis of breast cancer by integrating clinical and microarray data with Bayesian networks. Bioinformatics 2006;22: 184-90.
74. Li L. Survival prediction of diffuse large-B-cell lymphoma based on both clinical and gene expression information. Bioinformatics 2006;22:466-71.
75. Tibshirani R, Efron B. Pre-validation and inference in microarrays. Stat Appl GenetMol Biol 2007;1:1.
76. Binder H, Schumacher M. Allowing for mandatory covariates in boosting stimation of sparse high-dimensional survival models. BMC Bioinformatics 2008;9:14.
77. Boulesteix A, Porzelius C, Daumer M. Microarray-based classification and clinical predictors: on combined classifiers and additional predictive value. Bioinformatics 2008;24: 1698-706.
78. Le Cao K, Meugnier E, McLachlan GJ. Integrative mixture of experts to combine clinical factors and gene markers. Bioinformatics 2010. to appear.
79. Boulesteix A, Hothorn T. Testing the additional predictive value of high-dimensional molecular data. BMC Bioinformatics 2010;11:78.
80. Le Cao K, Gonzalez I, Dejean S. IntegrOmics: an R package to unravel relationships between two omics data sets. Bioinformatics 2009;25:2855-6.
81. Wang M, You J, Bemis KG, et al. Label-free mass spectrometry-based protein quantification technologies in proteomic analysis. Brief Funct Genomics Proteomics 2008;7: 329-39.
82. Wong JWH, Sullivan MJ, Cagney G. Computational methods for the comparative quantification of proteins in label-free LCn-MS experiments. Brief Bioinform 2008;9: 156-65.
83. Karpievitch YV, Taverner T, Adkins JN, et al. Normalization of peak intensities in bottom-up MS-based proteomics using singular value decomposition. Bioinformatics 2009;25:2573-80.
84. Yu T, Park Y, Johnson JM, Jones DP. apLCMS-adaptive processing of high-resolution LC/MS data. Bioinformatics 2009;25:1930-6.
85. Pham TV, Piersma SR, Warmoes M, et al. On the betabinomial model for analysis of spectral count data in labelfree tandem mass spectrometry-based proteomics. Bioinformatics 2010;26:363-9.
86. Wu WW, Wang G, Baek SJ, Shen RF. Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. J Proteome Res 2006;5:651-8.